10 results on '"Thorne, Claire"'
Search Results
2. High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk.
- Author
-
Aebi-Popp, Karoline, Bailey, Heather, Malyuta, Ruslan, Volokha, Alla, Thorne, Claire, and Ukraine European Collaborative Study in EuroCoord
- Subjects
HIV infections ,PREGNANCY ,HERPES simplex virus ,VERTICAL transmission (Communicable diseases) ,WOMEN ,HIV infection transmission ,HIV infection epidemiology ,COMMUNICABLE disease epidemiology ,COMMUNICABLE diseases ,COMPARATIVE studies ,EPIDEMIOLOGICAL research ,HERPES genitalis ,HERPESVIRUSES ,HIV ,RESEARCH methodology ,MEDICAL cooperation ,POISSON distribution ,PREGNANCY complications ,RESEARCH ,RESEARCH funding ,VIRAL antibodies ,LOGISTIC regression analysis ,EVALUATION research ,DISEASE prevalence ,MIXED infections ,INFECTIOUS disease transmission - Abstract
Background: Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk. We explored factors associated with HSV-2 seropositivity among HIV-positive women in Ukraine, and its impact on HIV MTCT.Methods: Data on 1513 HIV-positive women enrolled in the Ukraine European Collaborative Study from 2007 to 2012 were analysed. Poisson and logistic regression models respectively were fit to investigate factors associated with HSV-2 seropositivity and HIV MTCT.Results: Median maternal age was 27 years (IQR 24-31), 53% (796/1513) had been diagnosed with HIV during their most recent pregnancy and 20% had a history of injecting drugs. Median antenatal CD4 count was 430 cells/mm(3) (IQR 290-580). Ninety-six percent had received antiretroviral therapy antenatally. HSV-2 seroprevalence was 68% (1026/1513). In adjusted analyses, factors associated with HSV-2 antibodies were history of pregnancy termination (APR 1.30 (95% CI 1.18-1.43) for ≥ 2 vs. 0), having an HIV-positive partner (APR 1.15 (95% CI 1.05-1.26) vs partner's HIV status unknown) and HCV seropositivity (APR 1.23 (95 % CI 1.13-1.35)). The overall HIV MTCT rate was 2.80% (95% CI 1.98-3.84); no increased HIV MTCT risk was detected among HSV-2 seropositive women after adjusting for known risk factors (AOR 1.43 (95% CI 0.54-3.77).Conclusion: No increased risk of HIV MTCT was detected among the 68% of HIV-positive women with antibodies to HSV-2, in this population with an overall HIV MTCT rate of 2.8%. Markers of ongoing sexual risk among HIV-positive HSV-2 seronegative women indicate the importance of interventions to prevent primary HSV-2 infection during pregnancy in this high-risk group. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
- Author
-
Tookey, Pat A., Thorne, Claire, van Wyk, Jean, and Norton, Michael
- Subjects
- *
PREGNANCY complications , *HIV-positive persons , *ANTIRETROVIRAL agents , *OBSTETRICS , *HUMAN abnormalities , *BREASTFEEDING , *HIV infection transmission , *HETEROCYCLIC compounds , *ANTI-HIV agents , *HIV infection epidemiology , *RITONAVIR , *COMMUNICABLE disease epidemiology , *COMMUNICABLE diseases , *EVALUATION of medical care , *PREGNANCY , *PUBLIC health surveillance , *RESEARCH funding , *THERAPEUTICS , *VERTICAL transmission (Communicable diseases) , *PREVENTION - Abstract
Background: The National Study of HIV in Pregnancy and Childhood (NSHPC) conducts comprehensive population-based surveillance of pregnancies in women with HIV infection in the United Kingdom/Ireland. Use of antepartum antiretroviral therapy (ART) for prevention of mother-to-child transmission (MTCT) and to treat maternal infection, if required, is standard practise in this population; lopinavir/ritonavir (LPV/r) is commonly used. The study objective was to examine the use of LPV/r among pregnant women with HIV infection to describe maternal and foetal outcomes.Methods: The NSHPC study collected maternal, perinatal and paediatric data through confidential and voluntary obstetric and paediatric reporting schemes. Pregnancies reported to the NSHPC by June 2013, due to deliver 2003-2012 and with LPV/r exposure were included in this analysis, using pregnancy as the unit of observation.Results: Four thousand eight hundred sixty-four LPV/r-exposed pregnancies resulting in 4702 deliveries in 4118 women were identified. Maternal region of birth was primarily sub-Saharan Africa (77 %) or United Kingdom/Ireland (14 %). Median maternal age at conception was 30 years. LPV/r was initiated preconception in 980 (20 %) and postconception in 3884 (80 %) pregnancies; median duration of antepartum LPV/r exposure was 270 and 107 days, respectively. Viral load close to delivery was <50 copies/mL in 73 % and <1000 copies/mL in 94 % of women. 63 % of deliveries were by caesarean section (elective, 6 %; emergency, 38 %). Among singleton live births, 13 % were <37 weeks of gestation (2.5 % <32 weeks) and 15 % had birth weight <2500 g (2.3 % <1500 g). MTCT rates were 1.1 (2003-2007) and 0.5 % (2008-2012). 134 live born children (2.9 %) had ≥1 congenital abnormality.Conclusions: The results of this analysis using real-world data from a large number of pregnant women with HIV infection in the United Kingdom and Ireland who received LPV/r-containing ART regimens demonstrate that these regimens have a good safety profile and are effective for viral suppression during pregnancy, with associated low rates of MTCT. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10.
- Author
-
Thorne, Claire, Semenenko, Igor, and Malyuta, Ruslan
- Subjects
- *
HIV infection transmission , *ANTIRETROVIRAL agents , *ANALYSIS of variance , *CHI-squared test , *CONFIDENCE intervals , *EPIDEMIOLOGY , *HEALTH services accessibility , *HEALTH status indicators , *HIV infections , *LONGITUDINAL method , *EVALUATION of medical care , *SCIENTIFIC observation , *PREGNANCY , *PREGNANT women , *QUESTIONNAIRES , *RESEARCH funding , *SELF-evaluation , *STATISTICS , *LOGISTIC regression analysis , *DATA analysis , *INTRAVENOUS drug abusers , *DATA analysis software , *VERTICAL transmission (Communicable diseases) , *PREVENTION - Abstract
ABSTRACT Aims To compare clinical status, mother-to-child transmission (MTCT) rates, use of prevention of (PMTCT) interventions and pregnancy outcomes between HIV-infected injecting drug users (IDUs) and non-IDUs. Design and setting Prospective cohort study conducted in seven human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) Centres in Ukraine, 2000-10. Participants Pregnant HIV-infected women, identified before/during pregnancy or intrapartum, and their live-born infants ( n = 6200); 1028 women followed post-partum. Measurements Maternal and delivery characteristics, PMTCT prophylaxis, MTCT rates, preterm delivery (PTD) and low birth weight (LBW). Findings Of 6200 women, 1111 (18%) reported current/previous IDU. The proportion of IDUs diagnosed with HIV before conception increased from 31% in 2000/01 to 60% in 2008/09 ( P < 0.01). Among women with undiagnosed HIV at conception, 20% of IDUs were diagnosed intrapartum versus 4% of non-IDUs ( P < 0.01). At enrolment, 14% of IDUs had severe/advanced HIV symptoms versus 6% of non-IDUs ( P < 0.001). IDUs had higher rates of PTD and LBW infants than non-IDUs, respectively, 16% versus 7% and 22% versus 10% ( P < 0.001). IDUs were more likely to receive no neonatal or intrapartum PMTCT prophylaxis compared with non-IDUs (OR 2.81, p < 0.001). MTCT rates were 10.8% in IDUs versus 5.9% in non-IDUs; IDUs had increased MTCT risk (adjusted odds ratio 1.32, P = 0.049). Fewer IDUs with treatment indications received HAART compared with non-IDUs (58% versus 68%, P = 0.03). Conclusions Pregnant human immunodeficiency virus-infected injecting drug users in Ukraine have worse clinical status, poorer access to prevention of mother-to-child transmission prophylaxis and highly active antiretroviral therapy, more adverse pregnancy outcomes and higher risk of mother-to-child transmission than non-injecting drug user women. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Use of Neonatal Antiretroviral Prophylaxis for Prevention of Motherto-Child Transmission of HIV Is Decreasing in Western Europe.
- Author
-
England, Kirsty and Thorne, Claire
- Subjects
- *
LETTERS to the editor , *HIV infection transmission - Abstract
A letter to the editor is presented about the use of neonatal antiretroviral prophylaxis for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV).
- Published
- 2009
- Full Text
- View/download PDF
6. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA.
- Author
-
Newell, Marie-Louise, Huang, Sharon, Fiore, Simona, Thorne, Claire, Mandelbrot, Laurent, Sullivan, John L., Maupin, Robert, Delke, Isaac, Watts, Heather, Gelber, Richard D., and Cunningham, Coleen K.
- Subjects
HIV infection transmission ,PREGNANT women ,HIV-positive women ,PREGNANCY complications ,ANTIRETROVIRAL agents - Abstract
Background: Rates of mother-to-child transmission of HIV-1 (MTCT) have historically been lower in European than in American cohort studies, possibly due to differences in population characteristics. The Pediatric AIDS Clinical Trials Group Protocol (PACTG) 316 trial evaluated the effectiveness of the addition of intrapartum/neonatal nevirapine in reducing MTCT in women already receiving antiretroviral prophylaxis. Participation of large numbers of pregnant HIV-infected women from the US and Western Europe enrolling in the same clinical trial provided the opportunity to identify and explore differences in their characteristics and in the use of non-study interventions to reduce MTCT. Methods: In this secondary analysis, 1350 women were categorized according to enrollment in centres in the USA (n = 978) or in Europe (n = 372). Factors associated with receipt of highly active antiretroviral therapy and with elective caesarean delivery were identified with logistic regression. Results: In Europe, women enrolled were more likely to be white and those of black race were mainly born in Sub-Saharan Africa. Women in the US were younger and more likely to have previous pregnancies and miscarriages and a history of sexually transmitted infections. More than 90% of women did not report symptoms of their HIV infection; however, more women from the US had symptoms (8%), compared to women from Europe (4%). Women in the US were less likely to have HIV RNA levels <400 copies/ml at delivery than women enrolling in Europe, and more likely to receive highly active antiretroviral therapy, and to start therapy earlier in pregnancy. The elective caesarean delivery rate in Europe was 61%, significantly higher than that in the US (22%). Overall, 1.48% of infants were infected and there was no significant difference in the rate of transmission between Europe and the US despite the different approaches to treatment and delivery. Conclusion: These findings confirm that there are important historical differences between the HIV-infected pregnant populations in Western Europe and the USA, both in terms of the characteristics of the women and their obstetric and therapeutic management. Although highly active antiretroviral therapy predominates in pregnancy in both settings now, population differences are likely to remain. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
7. Vertically acquired paediatric coinfection with HIV and hepatitis C virus
- Author
-
England, Kirsty, Thorne, Claire, and Newell, Marie-Louise
- Subjects
- *
HIV , *HEPATITIS C virus , *HIV infection transmission , *INFECTIOUS disease transmission , *PREGNANCY , *PEDIATRICS , *VIRUS diseases - Abstract
Summary: Both HIV and hepatitis C virus (HCV) can be transmitted from mother to child during pregnancy and delivery. Vertical transmission of HIV and HCV separately is most likely from HIV/HCV-coinfected mothers; however, transmission of both infections is less frequent. The effect of HCV coinfection on HIV-related disease remains unclear; whereas most studies indicate no effect, recent results suggest HCV in adults accelerates HIV progression. Little is known about how HIV coinfection affects HCV progression in children and the information available is based on small numbers of patients. Paediatric HIV treatment is extremely successful and it is vital to determine if HCV coinfection alters the effectiveness of this treatment. The hepatotoxicity of many HIV therapies and the possible negative impact of HCV on this treatment, alongside the interactions and contraindications of many HIV and HCV therapies, further limits the choice of paediatric treatments for coinfected children. Future research must therefore focus on vertically acquired HIV/HCV coinfection to inform treatment trials addressing coinfection management. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. A New Piece in the Puzzle of Antiretroviral Therapy in Pregnancy and Preterm Delivery Risk.
- Author
-
Thorne, Claire and Townsend, Claire L.
- Subjects
- *
PREMATURE labor , *HIV-positive women , *HIV infection transmission , *ANTIRETROVIRAL agents - Abstract
The author reflects on various issues associated with preterm delivery in women suffering from human immunodeficiency virus (HIV) infection. Mother-to-child transmission is a major source of HIV transmission in children which can be significantly reduced through the widespread usage of combination antiretroviral therapy (ART). He also discusses a study conducted by Jeanne Sibiude from the French Perinatal Cohort concerned with the efficacy of ART in HIV-positive pregnant women.
- Published
- 2012
- Full Text
- View/download PDF
9. Mother-to-Child Transmission Risk Is Increased among HIV-Infected Pregnant Women in Ukraine with Serological Test Results Positive for Syphilis.
- Author
-
Thorne, Claire, Malyuta, Ruslan, Semenenko, Igor, Pilipenko, Tatyana, Stelmah, Andrej, Posokhova, Svetlana, and Newell1, Marie-Louise
- Subjects
- *
LETTERS to the editor , *HIV infection transmission - Abstract
A letter to the editor is presented which discusses the increased risk of mother-to-child transmission among human immunodeficiency virus (HIV)-infected pregnant women with serological tests positive for syphilis.
- Published
- 2008
- Full Text
- View/download PDF
10. Loss to follow-up of HIV-infected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study.
- Author
-
Aebi-Popp, Karoline, Kouyos, Roger, Bertisch, Barbara, Staehelin, Cornelia, Hoesli, Irene, Rickenbach, Martin, Thorne, Claire, Grawe, Claudia, Bernasconi, Enos, Cavassini, Matthias, Martinez de Tejada, Begona, Stoeckle, Marcel, Lecompte, Thanh, Rudin, Christoph, and Fehr, Jan
- Subjects
HIV-positive women ,HIV infection transmission ,PREGNANT women ,DELIVERY (Obstetrics) ,HIV infections - Abstract
Introduction HIV-infected pregnant women are very likely to engage in HIV medical care to prevent transmission of HIV to their newborn. After delivery, however, childcare and competing commitments might lead to disengagement from HIV care. The aim of this study was to quantify loss to follow-up (LTFU) from HIV care after delivery and to identify risk factors for LTFU. Methods We used data on 719 pregnancies within the Swiss HIV Cohort Study from 1996 to 2012 and with information on follow-up visits available. Two LTFU events were defined: no clinical visit for >180 days and no visit for >360 days in the year after delivery. Logistic regression analysis was used to identify risk factors for a LTFU event after delivery. Results Median maternal age at delivery was 32 years (IQR 28-36), 357 (49%) women were black, 280 (39%) white, 56 (8%) Asian and 4% other ethnicities. One hundred and seven (15%) women reported any history of IDU. The majority (524, 73%) of women received their HIV diagnosis before pregnancy, most of those (413, 79%) had lived with diagnosed HIV longer than three years and two-thirds (342, 65%) were already on antiretroviral therapy (ART) at time of conception. Of the 181 women diagnosed during pregnancy by a screening test, 80 (44%) were diagnosed in the first trimester, 67 (37%) in the second and 34 (19%) in the third trimester. Of 357 (69%) women who had been seen in HIV medical care during three months before conception, 93% achieved an undetectable HIV viral load (VL) at delivery. Of 62 (12%) women with the last medical visit more than six months before conception, only 72% achieved an undetectable VL (p=0.001). Overall, 247 (34%) women were LTFU over 180 days in the year after delivery and 86 (12%) women were LTFU over 360 days with 43 (50%) of those women returning. Being LTFU for 180 days was significantly associated with history of intravenous drug use (aOR 1.73, 95% CI 1.09-2.77, p=0.021) and not achieving an undetectable VL at delivery (aOR 1.79, 95% CI 1.03-3.11, p=0.040) after adjusting for maternal age, ethnicity, time of HIV diagnosis and being on ART at conception. Conclusions Women with a history of IDU and women with a detectable VL at delivery were more likely to be LTFU after delivery. This is of concern regarding their own health, as well as risk for sexual partners and subsequent pregnancies. Further strategies should be developed to enhance retention in medical care beyond pregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.